Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Cash & Equivalents (2016 - 2025)

ImmunityBio (IBRX) has disclosed Cash & Equivalents for 12 consecutive years, with $88.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 38.41% to $88.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $88.3 million, a 38.41% decrease, with the full-year FY2025 number at $88.3 million, down 38.41% from a year prior.
  • Cash & Equivalents was $88.3 million for Q4 2025 at ImmunityBio, up from $60.2 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $265.5 million in Q4 2023 to a low of $36.4 million in Q1 2022.
  • A 5-year average of $106.1 million and a median of $96.3 million in 2022 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: surged 418.69% in 2021, then plummeted 54.4% in 2025.
  • ImmunityBio's Cash & Equivalents stood at $181.1 million in 2021, then plummeted by 42.22% to $104.6 million in 2022, then skyrocketed by 153.68% to $265.5 million in 2023, then tumbled by 45.97% to $143.4 million in 2024, then tumbled by 38.41% to $88.3 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Cash & Equivalents are $88.3 million (Q4 2025), $60.2 million (Q3 2025), and $137.7 million (Q2 2025).